Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Kim, Daejin ^a,b   Hoory, Talia ^a   Monie, Archana ^a   Wu, Annie ^a   Hsueh, Wei Ting ^a,c   Pai, Sara I ^a   Hung, Chien Fu ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Chung Ang University   (South Korea)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

D 1515; DOXORUBICIN; LUCIFERASE; UNCLASSIFIED DRUG; DRUG CARRIER;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CONTACT; CELL DEATH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; IRRADIATION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DRUG THERAPY; EVALUATION; FLOW CYTOMETRY; METABOLISM; METHODOLOGY; OVARY TUMOR; RADIATION EXPOSURE; TUMOR CELL CULTURE;

MURINAE; MUS; MUS MUSCULUS;

ANIMALS; DOXORUBICIN; DRUG CARRIERS; DRUG THERAPY; FEMALE; FLOW CYTOMETRY; LUCIFERASES; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 77954875973     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-61     Document Type: Article

References (25)

1. Cancer statistics, 2006. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun, CA Cancer J Clin 2006 56 106 130 10.3322/canjclin.56.2.106 16514137
2. Cancer statistics, 2000. RT Greenlee T Murray S Bolden PA Wingo, CA Cancer J Clin 2000 50 7 33 10.3322/canjclin.50.1.7 10735013
3. Current diagnosis and treatment modalities for ovarian cancer. PE Schwartz, Cancer Treat Res 2002 107 99 118 11775463
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992 339 1 15 1345950
5. Biological fall our from trials of adjuvant tamoxifen in early ovarian cancer. M Baum S Ebb M Brooks, Adjuvant therapy of cancer WB. Saunders, Philadelphia, Salmon S, 1990 1 269 274
6. Selection of therapy for stage III breast cancer. SM Swain, Surg Clin North Am 1990 70 1061 1080 2218819
7. Recent patents therapeutic agents for cancer. X Li W Xu, Recent patents on anti-cancer drug discovery 2006 1 255 284 10.2174/157489206777442188 18221041
8. Doxorubicin (adriamycin) cardiomyopathy. E Saltiel W McGuire, West J Med 1983 139 332 341 6356608
9. Anthracycline-induced cardiotoxicity. AL Ferreira LS Matsubara BB Matsubara, Cardiovascular & hematological agents in medicinal chemistry 2008 6 278 281
10. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. T Simunek M Sterba O Popelova M Adamcova R Hrdina V Gersl, Pharmacol Rep 2009 61 154 171 19307704
11. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. TM Allen C Hansen F Martin C Redemann A Yau-Young, Biochim Biophys Acta 1991 1066 29 36 10.1016/0005-2736(91) 90246-5 2065067
12. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. KY Lin FG Guarnieri KF Staveley-O'Carroll HI Levitsky JT August DM Pardoll TC Wu, Cancer research 1996 56 21 26 8548765
13. Development of a syngeneic mouse model for events related to ovarian cancer. KF Roby CC Taylor JP Sweetwood Y Cheng JL Pace O Tawfik DL Persons PG Smith PF Terranova, Carcinogenesis 2000 21 585 591 10.1093/carcin/21.4.585 10753190
14. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. CF Hung YC Tsai L He TC Wu, Gene therapy 2007 14 921 929 10.1038/sj.gt.3302913 17377599
15. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. CF Hung YC Tsai L He G Coukos I Fodor L Qin H Levitsky TC Wu, Gene therapy 2007 14 20 29 10.1038/sj.gt.3302840 16915291
16. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. YQ Zhang YC Tsai A Monie TC Wu CF Hung, Mol Ther 18 692 699 10.1038/mt.2009.318 20087318
17. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. JC Tseng A Hurtado H Yee B Levin C Boivin M Benet SV Blank A Pellicer D Meruelo, Cancer research 2004 64 6684 6692 10.1158/0008-5472.CAN-04-1924 15374985
18. Systemic tumor targeting and killing by Sindbis viral vectors. JC Tseng B Levin A Hurtado H Yee I Perez de Castro M Jimenez P Shamamian R Jin RP Novick A Pellicer D Meruelo, Nature biotechnology 2004 22 70 77 10.1038/nbt917 14647305
19. Mechanism of doxorubicin-induced cell death and expression profile analysis. S Lee M Baek HY Kim JH Ha DI Jeoung, Biotechnol Lett 2002 24 1147 1151 10.1023/A:1016174800956 (Pubitemid 34823791)
20. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. CW Tseng CF Hung RD Alvarez C Trimble WK Huh D Kim CM Chuang CT Lin YC Tsai L He A Monie TC Wu, Clin Cancer Res 2008 14 3185 3192 10.1158/1078-0432.CCR-08-0037 18483387
21. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. CW Tseng A Monie C Trimble RD Alvarez WK Huh DJ Buchsbaum JM Straughn Jr MC Wang H Yagita CF Hung TC Wu, Vaccine 2008 26 4314 4319 10.1016/j.vaccine.2008.06.049 18598733
22. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. CW Tseng A Monie CY Wu B Huang MC Wang CF Hung TC Wu, Journal of molecular medicine (Berlin, Germany) 2008 86 899 908 18542898
23. Calreticulin exposure dictates the immunogenicity of cancer cell death. M Obeid A Tesniere F Ghiringhelli GM Fimia L Apetoh JL Perfettini M Castedo G Mignot T Panaretakis N Casares D Metivier N Larochette P van Endert F Ciccosanti M Piacentini L Zitvogel G Kroemer, Nature medicine 2007 13 54 61 10.1038/nm1523 17187072 (Pubitemid 46067386)
24. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. F Mohamed CF van der Walle, Journal of pharmaceutical sciences 2008 97 71 87 10.1002/jps.21082 17722085
25. Biodegradable polymers for microencapsulation of drugs. JH Park M Ye K Park, Molecules (Basel, Switzerland) 2005 10 146 161 18007283